Related Experiment Video
Updated: Feb 10, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
Published on: August 12, 2015
BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy
Hojjat Ahmadzadehfar, Florian Gaertner, Philipp S Lossin1
1Urological Center Bonn-Rhein-Sieg, Bonn, Germany.
Abstract:
We present the case of a 66-year-old man with castration-resistant prostate cancer, with an increasing prostate-specific antigen level, and a progressive disease during Lu-PSMA radionuclide therapy. Because the patient had a BRCA2 mutation, poly-ADP ribose polymerase inhibitor therapy was started. The patient showed a dramatic subjective and biological response to this therapy with a progression-free survival of 5 months.
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Viral Mutations
Gene Therapy
Mutation, Gene Flow, and Genetic Drift
Point and Frameshift Mutations

